摘要
恶性黑色素瘤是导致年轻人患癌症和癌症死亡的最普遍的原因之一。直到数年前,极少的药物证明在癌细胞转移治疗方面有效。但是,近些年,转移性恶性黑色素瘤的治疗采用了有效的疗法例如免疫疗法,络氨酸激酶抑制剂的使用和其他抑制细胞生长的化合物,像纳米粒子。这篇综述旨在提出一种根据化学性质来区分纳米粒子不同类型的标准,并更新纳米粒子的临床研究和它们在黑色素瘤治疗领域的应用。
关键词: 癌症,分类,黑素瘤,紫杉醇,纳米粒子
Current Medicinal Chemistry
Title:Nanoparticles in Melanoma
Volume: 21 Issue: 32
Author(s): M.A. Berciano-Guerrero, A. Montesa-Pino, G. Castaneda-Penalvo, L. Munoz-Fernandez and J. Rodriguez-Flores
Affiliation:
关键词: 癌症,分类,黑素瘤,紫杉醇,纳米粒子
摘要: Malignant melanoma is one of the most common causes of cancer and cancer deaths in young people. Until few years ago, scarce drugs have proven efficacy in metastatic setting. However, in the recent years, the treatment of metastatic malignant melanoma has undergone the incorporation of effective treatment such as immunotherapy, the use of tyrosine kinase inhibitors and the emergence of other cytostatic compounds, like the nanoparticles. This review aims to propose a standardization to classify the different types of nanoparticles, according to chemical aspects, and update the clinical research with nanoparticles and their use in melanoma field.
Export Options
About this article
Cite this article as:
Berciano-Guerrero M.A., Montesa-Pino A., Castaneda-Penalvo G., Munoz-Fernandez L. and Rodriguez-Flores J., Nanoparticles in Melanoma, Current Medicinal Chemistry 2014; 21 (32) . https://dx.doi.org/10.2174/0929867321666140716092512
DOI https://dx.doi.org/10.2174/0929867321666140716092512 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyphenols: Well Beyond The Antioxidant Capacity: Polyphenol Supplementation and Exercise-Induced Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines
Mini-Reviews in Medicinal Chemistry Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Mesenchymal Stem Cells Regulate Cytoskeletal Dynamics and Promote Cancer Cell Invasion Through Low Dose Nitric Oxide
Current Molecular Medicine Cytokine Gene Transfer into Dendritic Cells for Cancer Treatment
Current Gene Therapy Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines
Anti-Cancer Agents in Medicinal Chemistry Dendrimers and the Development of New Complex Nanomaterials for Biomedical Applications
Current Medicinal Chemistry Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry A State-of-the-art Review and Prospective Therapeutic Applications of Prenyl Flavonoids as Chemosensitizers against Antifungal Multidrug Resistance in <i>Candida albicans</i>
Current Medicinal Chemistry In Utero Gene Therapy: Prospect and Future
Current Pharmaceutical Design Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics
Current Drug Targets Metabolic and Amino Acid Alterations of the Tumor Microenvironment
Current Medicinal Chemistry Diagnosis and Management of Lynch Syndrome
Recent Patents on Regenerative Medicine The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Current Medicinal Chemistry Potential Therapeutic Applications of MDA-9/Syntenin-NF-κB-RKIP Loop in Human Liver Carcinoma
Current Molecular Medicine Anti-Aging Property of G2013 Molecule as a Novel Immunosuppressive Agent on Enzymatic and Non-Enzymatic Oxidative Stress Determinants in Rat Model
Current Drug Discovery Technologies Synthesis, Cytotoxicity Evaluation and Molecular Docking of Fluorine Containing Hexahydroquinoline-3-Carbonitrile Derivatives
Current Drug Discovery Technologies Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets